Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch to Ainuovirine/3TC/TDF for dyslipidaemia or weight gain in treatment-experienced adults with HIV-1 (48-week results)
ChiCTR2400079673Phase 4Not yet recruiting
- Sponsor
- Chengdu Public Health Clinical Medical Centre
- Start
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ainuovirine, lamivudine and tenofovir in Human immunodeficiency virus infection type 1, lipid disorder, N/A and 3 more, sponsored by Chengdu Public Health Clinical Medical Centre. Primary endpoint: Change in lipid profile at week 48. Planned start Jan 2024; status: not yet recruiting.
02
Drugs
ainuovirinelamivudinetenofovir
03
Conditions
Human immunodeficiency virus infection type 1lipid disorderN/Ainsulin resistance (IR)steatosis
Beyond the preview
Go deeper on ChiCTR2400079673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400079673.